Xencor Inc. (XNCR), a clinical-stage biopharmaceutical company, will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.
The same day, the company will furnish both a corporate update and a clinical update of its lead investigational drug Vudalimab in metastatic castration-resistant prostate cancer.
A phase II clinical study of Vudalimab in patients with metastatic castration-resistant prostate cancer (mCRPC) plus chemotherapy for certain patient populations, a phase II study in patients with clinically defined high-risk metastatic castration-resistant prostate cancer, and a phase Ib/II study evaluating Vudalimab plus standard-of-care chemotherapy as a first-line treatment in patients with advanced non-squamous, non-small cell lung cancer are underway.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.